Bilberry

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bilberry
Accession Number
DB14235
Description
Not Available
Type
Biotech
Groups
Approved, Experimental
Synonyms
  • Bilberry fruit
  • Dried billberry fruit (vaccinium myrtillus l.)
  • Dwarf bilberry
  • Dwarf bilberry fruit
  • European blueberry
  • European blueberry fruit
  • Fresh billberry fruit (vaccinium myrtillus l.)
  • Myrtilli fructus
  • Myrtilli fructus recens (vaccinium myrtillus l.)
  • Myrtilli fructus siccus (vaccinium myrtillus l.)
  • Myrtillus
  • Myrtle blueberry
  • Myrtle blueberry fruit
  • Myrtle whortleberry
  • Myrtle whortleberry fruit
  • Vaccinium myrtillus
  • Vaccinium myrtillus dry fruit
  • Vaccinium myrtillus fruit
  • Whortleberry
External IDs
  • B1064
  • B2013

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Bilberry Extract TabletsTabletOralAbundance Naturally LtdNot applicableNot applicableCanada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Prenate ChewableBilberry (25 mg/1) + Biotin (280 ug/1) + Boron (250 ug/1) + Calcium carbonate (500 mg/1) + Cholecalciferol (300 [iU]/1) + Cyanocobalamin (125 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (50 mg/1) + Pyridoxine hydrochloride (10 mg/1)Tablet, chewableOralAvion Pharmaceuticals, Llc2013-01-16Not applicableUS flag
VP-PrecipBilberry (40 mg/1) + Evening primrose oil (500 mg/1) + Linseed oil (1000 mg/1)Capsule, gelatin coatedOralVirtus Pharmaceuticals2012-05-182016-03-03US flag

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
9P2U39H18W
CAS number
Not Available

References

General References
Not Available
RxNav
125929
Wikipedia
Bilberry
AHFS Codes
  • 92:01.00* — Herbs and Natural Products

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnSupportive CareMucositis / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
Tablet, chewableOral
Capsule, gelatin coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on July 04, 2018 20:49 / Updated on October 27, 2020 11:13

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates